MY160951A - Mesenchymal stem cell differentiation - Google Patents

Mesenchymal stem cell differentiation

Info

Publication number
MY160951A
MY160951A MYPI2011006173A MYPI2011006173A MY160951A MY 160951 A MY160951 A MY 160951A MY PI2011006173 A MYPI2011006173 A MY PI2011006173A MY PI2011006173 A MYPI2011006173 A MY PI2011006173A MY 160951 A MY160951 A MY 160951A
Authority
MY
Malaysia
Prior art keywords
mesenchymal stem
present
stem cell
cell differentiation
provides
Prior art date
Application number
MYPI2011006173A
Other languages
English (en)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160951(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Novartis Ag filed Critical Scripps Research Inst
Publication of MY160951A publication Critical patent/MY160951A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2011006173A 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation MY160951A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
MY160951A true MY160951A (en) 2017-03-31

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011006173A MY160951A (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Country Status (30)

Country Link
US (4) US9139633B2 (OSRAM)
EP (1) EP2453921B1 (OSRAM)
JP (1) JP5602850B2 (OSRAM)
KR (3) KR20180000337A (OSRAM)
CN (2) CN102625830B (OSRAM)
AU (1) AU2010273570B2 (OSRAM)
BR (1) BR112012000914B8 (OSRAM)
CA (1) CA2767826C (OSRAM)
CL (1) CL2012000091A1 (OSRAM)
CO (1) CO6491059A2 (OSRAM)
CR (1) CR20120024A (OSRAM)
CU (1) CU24042B1 (OSRAM)
EA (1) EA023073B1 (OSRAM)
EC (1) ECSP12011604A (OSRAM)
ES (1) ES2541217T3 (OSRAM)
GT (1) GT201200011A (OSRAM)
IL (2) IL217383A (OSRAM)
IN (1) IN2012DN00572A (OSRAM)
MA (1) MA33423B1 (OSRAM)
MX (1) MX2012000707A (OSRAM)
MY (1) MY160951A (OSRAM)
NZ (1) NZ597306A (OSRAM)
PE (2) PE20120570A1 (OSRAM)
PL (1) PL2453921T3 (OSRAM)
PT (1) PT2453921E (OSRAM)
SG (1) SG177318A1 (OSRAM)
TN (1) TN2011000655A1 (OSRAM)
UA (1) UA104031C2 (OSRAM)
WO (1) WO2011008773A2 (OSRAM)
ZA (1) ZA201200078B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180000337A (ko) * 2009-07-14 2018-01-02 노파르티스 아게 중간엽 줄기 세포 분화
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
JP5969041B2 (ja) 2011-11-08 2016-08-10 エレクトロニクス アンド テレコミュニケーションズ リサーチ インスチチュートＥｌｅｃｔｒｏｎｉｃｓ Ａｎｄ Ｔｅｌｅｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 候補リスト共有方法及びこのような方法を使用する装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
EP3369747A1 (en) 2012-06-25 2018-09-05 The Brigham and Women's Hospital, Inc. Targeted theratpeutics
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CN105228626A (zh) 2013-03-15 2016-01-06 加州生物医学研究所 用于诱导软骨形成的化合物和方法
CA2947031C (en) 2014-05-13 2023-01-24 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
CA3016764A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
WO2018087727A1 (en) * 2016-11-14 2018-05-17 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
EP3891154B1 (en) 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO1999058660A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU4011300A (en) 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US7687460B2 (en) 2000-10-16 2010-03-30 Genentech, Inc, Methods of treatment using wisp polypeptides
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
JP4764630B2 (ja) * 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
CN101265503A (zh) * 2003-03-10 2008-09-17 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
AU2005258052B2 (en) * 2004-06-21 2008-11-27 The Cleveland Clinic Foundation CCR ligands for stem cell homing
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
KR20180000337A (ko) * 2009-07-14 2018-01-02 노파르티스 아게 중간엽 줄기 세포 분화
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
CA2767826C (en) 2015-11-24
GT201200011A (es) 2013-12-10
WO2011008773A2 (en) 2011-01-20
NZ597306A (en) 2014-03-28
US10555990B2 (en) 2020-02-11
US20160213748A1 (en) 2016-07-28
EA201200118A1 (ru) 2012-09-28
MA33423B1 (fr) 2012-07-03
US20190000922A1 (en) 2019-01-03
KR101590834B1 (ko) 2016-02-12
CN102625830A (zh) 2012-08-01
TN2011000655A1 (en) 2013-05-24
EP2453921A4 (en) 2012-12-19
BR112012000914A2 (pt) 2017-08-08
CR20120024A (es) 2012-06-11
JP5602850B2 (ja) 2014-10-08
US20120177644A1 (en) 2012-07-12
IL217383A0 (en) 2012-02-29
IL217383A (en) 2016-08-31
AU2010273570B2 (en) 2014-07-03
PE20120570A1 (es) 2012-05-19
CN105601728B (zh) 2020-01-10
BR112012000914A8 (pt) 2017-12-19
MX2012000707A (es) 2012-03-21
ES2541217T3 (es) 2015-07-16
PL2453921T3 (pl) 2015-11-30
JP2012533549A (ja) 2012-12-27
KR20160015403A (ko) 2016-02-12
ECSP12011604A (es) 2012-06-29
ZA201200078B (en) 2013-01-30
AU2010273570A1 (en) 2012-02-02
BR112012000914B1 (pt) 2021-04-06
PE20160507A1 (es) 2016-05-20
CA2767826A1 (en) 2011-01-20
US20200108122A1 (en) 2020-04-09
UA104031C2 (uk) 2013-12-25
US9139633B2 (en) 2015-09-22
US10064918B2 (en) 2018-09-04
KR20120029472A (ko) 2012-03-26
PT2453921E (pt) 2015-09-25
SG177318A1 (en) 2012-03-29
KR20180000337A (ko) 2018-01-02
CO6491059A2 (es) 2012-07-31
CU20120007A7 (es) 2013-02-26
EA023073B1 (ru) 2016-04-29
EP2453921B1 (en) 2015-05-27
IL247310B (en) 2018-04-30
CL2012000091A1 (es) 2012-10-26
WO2011008773A3 (en) 2011-08-25
CN105601728A (zh) 2016-05-25
CN102625830B (zh) 2016-03-02
US11241482B2 (en) 2022-02-08
BR112012000914B8 (pt) 2021-05-25
HK1164169A1 (en) 2012-09-21
IN2012DN00572A (OSRAM) 2015-06-12
EP2453921A2 (en) 2012-05-23
CU24042B1 (es) 2014-11-27

Similar Documents

Publication Publication Date Title
MY160951A (en) Mesenchymal stem cell differentiation
Chen et al. Mesenchymal stem cells in arthritic diseases
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011091420A3 (en) Osteogenic cell delivery matrix
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
NZ605871A (en) Treatment of sanfilippo syndrome type b
Im et al. Regenerative therapy for osteoarthritis: a perspective
MX2010003574A (es) Anticuerpos il-23.
MX2011013722A (es) Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
WO2009100035A3 (en) Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
MX388960B (es) Una población de células madre mesenquimales enriquecida en integrina a10alta y su uso en la prevención y tratamiento de daño o enfermedad ósea y cartílago.
WO2010033088A8 (en) Method of improving differentiation of chondrogenic progenitor cells
Pei et al. Response of human periodontal ligament cells to baicalin
SG10201908916UA (en) Stable MIA/CD-RAP formulations
IL173544A0 (en) Use of cxcl6 chemokine in the prevention or repair of cartilage defects
WO2014204806A3 (en) Adipose cells for chondrocyte applications
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
UY33219A (es) Cetoenoles cíclicos para terapias
GB201213571D0 (en) Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.
Pawitan et al. Prospect of umbilical cord mesenchymal stem cell culture waste in regenerative medicine
IN2012DN05181A (OSRAM)
WO2004071443A3 (en) Methods and compositions for modulating stem cells
Ravanbod et al. Experimental study on the role of intra‐articular injection of MSCs on cartilage regeneration in haemophilia
Guilak et al. Journal of Orthopaedic Research: Special Issue on Stem Cells.